Ardelyx (ARDX) Competitors

Ardelyx (NASDAQ:ARDX) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Which has more volatility & risk, ARDX or CYTK?

Ardelyx has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Is ARDX or CYTK more profitable?

Ardelyx has a net margin of -28.82% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-28.82%	-46.60%	-21.49%
Cytokinetics	-17,906.25%	N/A	-50.21%

Does the media refer more to ARDX or CYTK?

In the previous week, Cytokinetics had 7 more articles in the media than Ardelyx. MarketBeat recorded 17 mentions for Cytokinetics and 10 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.37 beat Cytokinetics' score of 0.13 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders believe in ARDX or CYTK?

58.9% of Ardelyx shares are held by institutional investors. 5.9% of Ardelyx shares are held by insiders. Comparatively, 3.4% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has higher valuation & earnings, ARDX or CYTK?

Ardelyx has higher revenue and earnings than Cytokinetics. Ardelyx is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$124.46M	11.09	-$66.07M	-$0.30	-19.42
Cytokinetics	$7.53M	778.19	-$526.24M	-$5.38	-9.23

Do analysts recommend ARDX or CYTK?

Ardelyx currently has a consensus target price of $9.42, suggesting a potential upside of 61.66%. Cytokinetics has a consensus target price of $82.00, suggesting a potential upside of 65.14%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts plainly believe Cytokinetics is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88
Cytokinetics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94

Does the MarketBeat Community favor ARDX or CYTK?

Cytokinetics received 284 more outperform votes than Ardelyx when rated by MarketBeat users. Likewise, 79.92% of users gave Cytokinetics an outperform vote while only 67.43% of users gave Ardelyx an outperform vote.

Company	Underperform	Outperform
Ardelyx	Outperform Votes 532 67.43%	Underperform Votes 257 32.57%
Cytokinetics	Outperform Votes 816 79.92%	Underperform Votes 205 20.08%

Summary

Ardelyx and Cytokinetics tied by winning 9 of the 18 factors compared between the two stocks.